Frankfurt - Delayed Quote EUR

Viking Therapeutics, Inc. (1VT.F)

Compare
60.78 +1.58 (+2.67%)
As of 9:21 AM GMT+2. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
124,677.00
100,827.00
70,355.00
55,682.00
42,662.00
--
Operating Income
-124,677.00
-100,827.00
-70,355.00
-55,682.00
-42,662.00
--
Net Non Operating Interest Income Expense
27,930.00
14,932.00
1,530.00
685.00
3,127.00
--
Other Income Expense
--
--
-42.00
7.00
40.00
4.00
Pretax Income
-96,745.00
-85,895.00
-68,867.00
-54,990.00
-39,495.00
--
Net Income Common Stockholders
-96,745.00
-85,895.00
-68,867.00
-54,990.00
-39,495.00
--
Diluted NI Available to Com Stockholders
-96,745.00
-85,895.00
-68,867.00
-54,990.00
-39,495.00
--
Basic EPS
-0.93
-0.91
-0.90
-0.71
-0.54
--
Diluted EPS
-0.93
-0.91
-0.90
-0.71
-0.54
--
Basic Average Shares
103,439.94
94,347.00
76,834.00
77,198.00
72,597.00
--
Diluted Average Shares
103,439.94
94,347.00
76,834.00
77,198.00
72,597.00
--
Total Operating Income as Reported
-124,677.00
-100,827.00
-70,355.00
-55,682.00
-42,662.00
--
Total Expenses
124,677.00
100,827.00
70,355.00
55,682.00
42,662.00
--
Net Income from Continuing & Discontinued Operation
-96,745.00
-85,895.00
-68,867.00
-54,990.00
-39,495.00
--
Normalized Income
-96,747.00
-85,895.00
-68,825.00
-54,997.00
-39,535.00
--
Interest Income
28,004.00
15,020.00
1,589.00
703.00
3,233.00
--
Net Interest Income
27,930.00
14,932.00
1,530.00
685.00
3,127.00
--
EBIT
-124,677.00
-100,827.00
-70,355.00
-55,682.00
-42,662.00
--
EBITDA
-124,381.00
-100,535.00
-70,064.00
-55,386.00
-42,385.00
--
Reconciled Depreciation
296.00
292.00
291.00
296.00
277.00
--
Net Income from Continuing Operation Net Minority Interest
-96,745.00
-85,895.00
-68,867.00
-54,990.00
-39,495.00
--
Total Unusual Items Excluding Goodwill
2.00
--
-42.00
7.00
40.00
4.00
Total Unusual Items
2.00
--
-42.00
7.00
40.00
4.00
Normalized EBITDA
-124,383.00
-100,535.00
-70,022.00
-55,393.00
-42,425.00
--
12/31/2019 - 5/11/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers